44 / 64
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 31, No 3, May/June 2020
152
AFRICA
pathogenesis of atherosclerosis: an overview.
Clin Cardiol
1991;
14
:
11–16.
25. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander
RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in
atherosclerotic coronary arteries.
N Engl J Med
1986;
315
: 1046–1051.
26. Rodbars S, Ikeda K, Montes M. Ananalysis of mechanism of poststen-
otic dilatation.
Angiology
1967;
18
: 349.
27. Nachtigal M, AI-Assaad Z, Mayer EP, Kim K, Monsigny M. Galectin-3
expression in humanatherosclerotic lesions.
Am J Pathol
1998;
152
:
1199–1208.
28. Sano H, Hsu OK, Yu L, Apgar JR, Kuwabara I, Yamanaka T,
et
al
. Human galectin-3 is a novel chemoattractant for monocytes and
macrophages.
J Immunol
2000;
165
: 2156–2164.
29. Vlassara H, Li YM, Imani F, Wojciechowicz O, Yang Z, Liu FT,
Cerami A. Identification of galectin-3 as a high-affinity binding protein
for advanced glycation end products (AGE): a new member of the
AGE-receptor complex.
Mol Med
1995;
1
(6): 634–646.
30. Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The
role of galectin-3 in endocytosis of advanced glycation end products
and modified low density lipoproteins.
Biochem Biophys Res Commun
2001;
280
: 1183–1188.
31. Rubinstein N, Ilarregui JM, Toscano MA,
et al.
The role of galectins
in the initiation, amplification and resolution of the inflammatory
response.
Tissue Antigens
2004;
64
: 1–12.
32. Tian L, Chen K, Cao J, Han Z, Gao L, Wang Y,
et al
. Galectin-3-
induced oxidized low-density lipoprotein promotes the phenotypic
transformation of vascular smooth muscle cells.
Mol Med Rep
2015;
12
(4): 4995–5002.
33. Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE, Benito-Martin
A, Burillo E, Zalba G,
et al
. Galectin-3, a biomarker linking oxidative
stress and inflammation with the clinical outcomes of patients with
atherothrombosis.
J Am Heart Assoc
2014;
3
(4): pii: e000785.
34. Winter MP, Wiesbauer F, Alimohammadi A, Blessberger H, Pavo N,
Schillinger M,
et al
. Soluble galectin-3 is associated with premature
myocardial infarction.
Eur J Clin Invest
2016;
46
(5): 386–391.
35. Aksan G, Gedikli Ö, Keskin K, Nar G,
İ
nci S, Yıldız SS,
et al
. Is galec-
tin-3 a biomarker, a player-or both-in the presence of coronary athero-
sclerosis?
J Investig Med
2016;
64
(3): 764–770.
36. Kadoglou NP, Sfyroeras GS, Spathis A, Gkekas C, Gastounioti A,
Mantas G,
et al
. Galectin-3, carotid plaque vulnerability, and potential
effects of statin therapy.
Eur J Vasc Endovasc Surg
2015;
49
(1): 4–9.
37. Tsai TH, Sung PH, Chang LT,
et al
. Value and level of galectin-3 acute
myocardial infarction patients undergoing primary percutaneous coro-
nary intervention
. J Atheroscler Thromb
2012;
19
: 1073–1082.
38. Falcone C, Lucibello S, Mazzucchelli I,
et al
. Galectin-3 plasma levels
and coronary artery disease: a new possible biomarker of acute coro-
nary syndrome.
Int J Immunopathol Pharmacol
2011;
24
: 905–913.
39. Özturk D, Celik Ö, Satılmıs S,
et al
. Association between serum galec-
tin-3 levels and coronary atherosclerosis and plaque burden/structure
in patients with type 2 diabetes mellitus.
Coron Artery Dis
2015;
26
:
396–401.
40. Maiolino G, Rossitto G, Pedon L,
et al
. Galectin-3 predicts long-term
cardiovascular death in high-risk patients with coronary artery disease.
Arterioscler Thromb Vasc Biol
2015;
35
: 725–732.